Premium
Albumin purification from human placenta
Author(s) -
CabreraCrespo Joaquin,
Gonçalves Viviane Maimoni,
Martins Elizabeth A. L.,
Grellet Sheyla,
Lopes Alexandre Paulo Yague,
Raw Isaías
Publication year - 2000
Publication title -
biotechnology and applied biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 70
eISSN - 1470-8744
pISSN - 0885-4513
DOI - 10.1042/ba19990095
Subject(s) - diafiltration , chromatography , chemistry , ultrafiltration (renal) , albumin , centrifugation , size exclusion chromatography , extraction (chemistry) , membrane , biochemistry , microfiltration , enzyme
Albumin is the human protein used mainly for therapeutic purposes. Besides the traditionally used plasma, blood from placenta is an alternative source for albumin purification. We describe here an industrial process for purification of albumin from human placenta. The proposed albumin‐purification process, for 50 kg of placentas, comprises: (i) extraction of haemolysed blood with saline and solid/liquid separation by basket centrifugation; (ii) selective precipitation of haemoglobin by ethanol/chloroform and precipitate removal by filtration in a press filter; (iii) concentration/diafiltration of the filtrate in a 30 kDa cross‐flow ultrafiltration (CFUF) membrane; (iv) thermo‐coagulation at 70 °C with sodium octanoate/EDTA; (v) treatment with activated charcoal at pH 3; (vi) concentration/diafiltration of the filtrate in a 30 kDa CFUF membrane; (vii) anion‐exchange chromatography Q‐Sepharose; (viii) hydrophobic‐interaction chromatography with phenyl‐Sepharose; and (ix) conditioning and pasteurization. The process yields an average of 4.5 g of albumin/kg of placenta with a purity of 97.1% and A 403 of 0.05 (1% protein). The final product passes pyrogen and toxicity tests in vivo and it does not contain polymers or aggregates, even after the accelerated stability test, as judged by gel filtration, as required by the Brazilian Pharmacopoeia.